Home Health Bi-weekly dose of Johnson & Johnson’s blood most cancers remedy will get US FDA approval – ET HealthWorld | Pharma

Bi-weekly dose of Johnson & Johnson’s blood most cancers remedy will get US FDA approval – ET HealthWorld | Pharma

0
Bi-weekly dose of Johnson & Johnson’s blood most cancers remedy will get US FDA approval – ET HealthWorld | Pharma

[ad_1]

Washington DC: The U.S. Food and Drug Administration has permitted a bi-weekly dose of Johnson & Johnson’s blood cancer remedy Tecvayli, the drugmaker mentioned on Tuesday.

The approval permits the remedy for use in a lowered dosing of 1.5 milligrams per kilogram each two weeks, in sufferers who’ve achieved and maintained a whole response or higher for no less than six months.

Tecvayli was first permitted in October 2022 for the therapy of adults with a number of myeloma that’s exhausting to deal with, or has come again after receiving a minimum of 4 prior strains of sure courses of therapies.

A number of myeloma is a sort of blood most cancers that impacts kinds of white blood cells referred to as plasma cells, present in bone marrow.

  • Printed On Feb 21, 2024 at 03:03 PM IST

Be part of the neighborhood of 2M+ trade professionals

Subscribe to our e-newsletter to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles


Scan to obtain App


[ad_2]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here